A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) (PERSPECTIVE)

Astellas

Status

Completed

Conditions

Urinary Bladder Diseases

Urinary Bladder Overactive

Urologic Diseases

Overactive Bladder

Treatments

Drug: antimuscarinic medication

Drug: mirabegron

Study type

Observational

Funder types

Industry

Identifiers

NCT02386072

178-MA-1006

Details and patient eligibility

About

A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form)

Enrollment

1,524 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosed with OAB (with or without urgency incontinence) by the treating HCP, with symptoms for at least three months prior to study enrollment
Initiating a new course of treatment with mirabegron or antimuscarinic medication (including patch formulation) for OAB, which may be first course of any treatment for OAB, restart or switch from one drug to another
Willing and able to complete PRO questionnaires with minimal assistance

Exclusion criteria

Current participation in clinical trials of OAB
Use of more than one OAB medication at time of enrollment
Patients whose OAB has been treated with onabotulinumtoxinA, sacral neuromodulation, percutaneous tibial nerve stimulation, external beam radiation (XRT), stents, surgery, or intermittent catheterization prior to or at time of enrollment
Neurologic conditions associated with OAB symptoms
Patients residing in a nursing home